公开(公告)号：US20240294546A1

公开(公告)日：2024-09-05

申请号：US18368244

申请日：2023-09-14

申请人： Novartis AG

发明人： David R. Anderson ,  Robert A. Volkmann ,  Frank S. Menniti ,  Christopher Fanger ,  Yuelian Xu

IPC分类号： C07D513/04 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/20

CPC分类号： C07D513/04 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/20

摘要： Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

公开(公告)号：US11648253B2

公开(公告)日：2023-05-16

申请号：US17458797

申请日：2021-08-27

申请人： Novartis AG

发明人： David R. Anderson ,  Robert A. Volkmann ,  Frank S. Menniti ,  Christopher Fanger

IPC分类号： A61K31/519 ,  C07D495/04 ,  A61P25/28 ,  A61P25/18 ,  A61P25/24

CPC分类号： A61K31/519 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D495/04

摘要： Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

公开(公告)号：US20240199617A1

公开(公告)日：2024-06-20

申请号：US18221694

申请日：2023-07-13

申请人： Novartis AG

发明人： David R. Anderson ,  Robert A. Volkmann ,  Gregg F. Keaney ,  Steven C. Leiser ,  Sam Malekiani ,  Timothy Piser

IPC分类号： C07D487/04 ,  A61P25/28

CPC分类号： C07D487/04 ,  A61P25/28

摘要： Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.